A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advan

A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants is a phase 3, randomised interventional study registered as NCT07756645 by AbbVie, with a registry enrolment figure of 940 participants, started 2026-09-22 and due to reach its primary completion in 2029-12. Interventions recorded: ABBV-1480; Pembrolizumab; Carboplatin; Paclitaxel; Nab- Paclitaxel. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Progression-Free Survival (PFS) assessed by the Blinded Independent Central Review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; Overall Survival (OS). Lung eligibility wording from the registry: "* Adult subjects with a histologically or cytologically confirmed diagnosis of Stage IIIB, IIIC, or IV sqNSCLC that is not amenable to curative treatment". No results are recorded here; the registry entry is the source.